bivalirudin + clopidogrel + aspirin

The combination of bivalirudin, clopidogrel, and aspirin is used in the management of acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). This is a specific anticoagulant and antiplatelet therapy regimen rather than a single formulated product. ## Description This is a combination anticoagulant and antiplatelet therapy used primarily in patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome. Each component plays a specific role: - **Bivalirudin** is a direct thrombin inhibitor that prevents blood clotting. It's a synthetic peptide derived from hirudin found in medicinal leech saliva, providing predictable anticoagulation with a short half-life and lower bleeding risk compared to heparin. - **Clopidogrel** is an antiplatelet agent that inhibits platelet aggregation by irreversibly blocking the P2Y12 receptor, preventing platelets from clumping together to form clots. - **Aspirin** provides additional antiplatelet effects through inhibition of cyclooxygenase enzymes, reducing the production of thromboxane A2. This combination therapy is particularly valuable for patients undergoing coronary procedures who need effective anticoagulation with reduced bleeding risk compared to traditional heparin-based regimens.

Other names

aspirin + clopidogrel + bivalirudinacetylsalicylic acid + clopidogrel + bivalirudin